title: [Diabetic retinopathy].
abstract: Diabetic retinopathy is a major cause of vision loss in Japan. Recent progress in the treatments of diabetic retinopathy includes the use of pattern scan laser photocoagulation, subthreshold micropulse laser photocoagulation, and micro incision vitreous surgery with chandelier illumination and wide-angle viewing system. The use of triamcinolone, indocyanine green or brilliant blue G, which are used to visualize the vitreous and the internal limiting membrane, respectively, has greatly facilitated vitreous surgery. As for intraocular drug therapy, antivascular endothelial growth factor agents are now available for diabetic retinopathy, useful not only for treating diabetic macular edema, but also for controlling bleeding during vitreous surgery and for temporarily suppressing the symptoms of proliferative diabetic retinopathy.
authors.forename: Harumi
authors.initials: H
authors.lastname: Fukushima
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kato
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use; D003930:Diabetic Retinopathy / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy*; D018450:Disease Progression; D006801:Humans; D017075:Laser Coagulation; D013256:Steroids / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D000906:Antibodies; D013256:Steroids; D042461:Vascular Endothelial Growth Factor A